HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...

Dupilumab is suggested for individuals aged 12 years or older and for pediatric patients who are nonresponsive to PPI therapy. Omalizumab is not suggested for EoE treatment. For esophageal ...

The guidelines support use of PPIs, dietary therapy, and biologics for EoE, and stress the importance of addressing both the inflammatory and fibrostenotic aspects of the disease.

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody for the treatment of eosinophilic esophagitis, or EoE, due to esophageal inflammation. It works on the mechanism of inhibiting IL-4 and ...

In particular, after dupilumab histological remission (defined as <15 eos/hpf) was achieved in up to 80% of cases, EREFS score decreased significantly from baseline and esophageal stricture diameter ...

Medically reviewed by Qin Rao, MD Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, the tube that carries food and liquids from the mouth to the stomach. EoE ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to study results. Image: Adobe Stock ...